Expert perspectives with George Demetri, MD

This independent medical education activity features expert interviews focusing on important data from the recent oncology literature in the field of gastrointestinal stromal tumors (GIST).

George Demetri, MD, is interviewed on the publication of results of the B2222 PK study, which demonstrated that imatinib plasma levels correlated with clinical benefit in patients with unresectable GIST.

George Demetri, MD Director of the Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Associate Professor of Medicine, Harvard University, Boston, Massachusetts, United States

Disclaimer: The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indications where you practice.

This Webcast is available from 1 July 2009 to 1 July 2010.

This activity is supported by an unrestricted educational grant from Novartis Oncology.